Table 4.

Cox regression analyses to predict risk factors for survival

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, per 1 year	1.013 (0.964-1.063)	0.620	1.039 (0.951-1.136)	0.395
Gender, male vs. female	1.196 (0.338-4.237)	0.782	2.407 (0.257-22.579)	0.442
Etiology		0.060		0.069
HBV vs. alcohol	2.212 (0.714-6.851)	0.169	5.79 (1.131-29.652)	0.035
HCV vs. alcohol	10.076 (1.195-55.306)	0.018	26.304 (0.749-923.218)	0.072
Baseline child score, per 1 score	0.932 (0.535-1.622)	0.803	1.625 (0.545-4.842)	0.383
Baseline tumor number, 3 or more vs. 1-2	0.798 (0.104-6.122)	0.828	0.053 (0.002-1.701)	0.097
Baseline tumor size, per 1 mm	1.006 (0.993-1.019)	0.339	1.018 (0.979-1.058)	0.373
Baseline tumor type, diffuse infiltrative vs. nodular	0.979 (0.404-2.371)	0.962	1.093 (0.148-8.064)	0.930
Baseline tumor extent, unilobar vs. bilobar	0.992 (0.410-2.399)	0.985	0.391 (0.057-2.693)	0.340
Baseline PVI level, Vp1-3 vs. Vp4	0.659 (0.270-1.606)	0.359	0.399 (0.026-6.198)	0.511
Baseline distant metastases, yes vs. none	3.290 (0.394-27.437)	0.271	1.946 (0.014-266.438)	0.791
Baseline HCC treatment, yes vs. no	1.117 (0.366-3.405)	0.846	4.339 (0.454-41.480)	0.203
Baseline Log(AFP), per 1 ng/mL	1.140 (0.777-1.673)	0.504	0.994 (0.472-2.094)	0.988
Baseline Log(PIVKA-II), per 1 mAU/mL	1.413 (0.904-2.208)	0.130	1.024 (0.370-2.827)	0.964

HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; PVI, portal vein invasion; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II.